financetom
Business
financetom
/
Business
/
Bank of Nova Scotia Fiscal Q2 Earnings Fall, Revenue Increases
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Bank of Nova Scotia Fiscal Q2 Earnings Fall, Revenue Increases
May 28, 2024 3:54 AM

06:39 AM EDT, 05/28/2024 (MT Newswires) -- Bank of Nova Scotia ( BNS ) (BNS) reported fiscal Q2 adjusted earnings Tuesday of CA$1.58 ($1.16) per diluted share, down from CA$1.69 a year earlier.

Analysts polled by Capital IQ expected CA$1.56.

Revenue for the quarter ended April 30 expressed as the sum of net interest income and total noninterest income was CA$8.35 billion, up from CA$7.91 billion a year earlier.

Analysts surveyed by Capital IQ expected CA$8.33 billion.

Price: 48.61, Change: +0.83, Percent Change: +1.74

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Actuate Therapeutics Gets Orphan Medicinal Product Label for Elraglusib in EU
Actuate Therapeutics Gets Orphan Medicinal Product Label for Elraglusib in EU
Jan 7, 2025
10:34 AM EST, 01/07/2025 (MT Newswires) -- Actuate Therapeutics ( ACTU ) said Tuesday that the European Medicines Agency has granted orphan medicinal product designation to elraglusib for the treatment of pancreatic ductal adenocarcinoma. The company said the designation is granted to therapies intended for the treatment of life-threatening diseases that affect no more than two in 10,000 people in...
Rezolute Says it Gets Breakthrough Therapy Designation From US FDA for Ersodetug to Treat Hypoglycemia
Rezolute Says it Gets Breakthrough Therapy Designation From US FDA for Ersodetug to Treat Hypoglycemia
Jan 7, 2025
10:34 AM EST, 01/07/2025 (MT Newswires) -- Rezolute ( RZLT ) said Tuesday it has received the US Food and Drug Administration's Breakthrough Therapy designation for its ersodetug monoclonal antibody to treat hypoglycemia due to congenital hyperinsulinism. The regulator's decision was based on the company's phase 2b trial of ersodetug in patients with congenital hyperinsulinism, which safely showed significant improvements...
NEO Battery Materials Launches New Product Line With
NEO Battery Materials Launches New Product Line With "Breakthrough" Battery Capacity
Jan 7, 2025
10:30 AM EST, 01/07/2025 (MT Newswires) -- NEO Battery Materials ( NBMFF ) on Tuesday announced the launch of an advanced high-performance silicon anode product with breakthrough battery capacity. The NBMSiDE P-300 product line showed a 43% to 130% improvement in initial battery capacity over traditional graphite anodes with less material used, the company said. NEO, which has submitted a...
Update: JPMorgan to Leave Net-Zero Banking Alliance
Update: JPMorgan to Leave Net-Zero Banking Alliance
Jan 7, 2025
10:35 AM EST, 01/07/2025 (MT Newswires) -- (Updates throughout with JPMorgan's ( JPM ) comments.) JPMorgan ( JPM ) is leaving climate group Net-Zero Banking Alliance, a company spokesperson told MT Newswires Tuesday. We will continue to work independently to advance the interests of our firm, our shareholders and our clients and remain focused on pragmatic solutions to help further...
Copyright 2023-2025 - www.financetom.com All Rights Reserved